Highlights Allakos Inc.

Equities

ALLK

US01671P1003

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
1.29 ^USD	+2.38%		+17.27%	-52.75%

03-15	North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	DJ
03-14	Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition	02-12	CI
Allakos to stop further development of skin disease drug, plans job cuts	01-16	RE
Allakos says experimental skin disease drug fails mid-stage studies	01-16	RE
Allakos Announces Restructuring to Focus on Development of AK006	01-16	CI
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	01-16	CI
Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	06/03/23	AQ
Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	06/03/23	CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	06/03/23	CI
ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	07/11/22	AQ
Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	07/11/22	CI
Allakos Inc. Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria	12/09/22	CI
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis	09/09/22	CI
ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	04/08/22	AQ
Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Allakos Q1 Loss Widens from Year Ago -- Stock Down Near 3% After-Hours	06/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Allakos Inc.

Equities

ALLK

US01671P1003

Highlights

Filters